Tatva Chintan Pharma Share News - Latest Updates, Live News & More

Latest news about Tatva Chintan Pharma

Tatva Chintan Pharma Files SEBI Takeover Disclosure for Promoter Share Transfer 7 days ago

Tatva Chintan Pharma Chem Limited has completed regulatory filings under SEBI Takeover Regulations for the transfer of 7,15,345 equity shares (3.06%) from Ajay Mansukhlal Patel (HUF) to the individual promoter following HUF dissolution. The transaction, executed without monetary consideration, increases the individual promoter's holding from 17.10% to 20.16% while maintaining overall promoter group commitment.

Ajay Mansukhlal Patel to Acquire 7,15,345 Equity Shares in Tatva Chintan Pharma Chem Through HUF Dissolution Jan 29, 2026

Tatva Chintan Pharma Chem Projects ₹200-250 Crores Revenue from New Intermediates by 2027 Jan 22, 2026

Tatva Chintan Pharma Chem Announces ₹250-275 Crore Greenfield Plant at Jolva Jan 22, 2026

Tatva Chintan Pharma Chem Targets 20-22% EBITDA Margins by FY27 Through Enhanced Plant Utilization Jan 22, 2026

More news about Tatva Chintan Pharma

22Jan 26

Tatva Chintan Pharma Chem Targets 20-30% Revenue Growth for FY26 and FY27

Tatva Chintan Pharma Chem has provided revenue growth guidance for FY26 and FY27, targeting year-on-year growth of 20% to 30%. The company considers these targets achievable based on current market conditions and operational capabilities. This guidance was shared during a conference call update, reflecting management's confidence in the company's strategic direction and growth trajectory.

22Jan 26

Tatva Chintan Pharma Chem Projects ₹850-900 Crores Revenue from Current Capacity

Tatva Chintan Pharma Chem Limited management has projected achieving overall revenue of ₹850.00-₹900.00 crores from current operational capacity within 2.5-3 years. This guidance, shared during a recent conference call, reflects the company's strategic focus on maximizing existing infrastructure utilization to drive substantial revenue growth without requiring significant additional capital investment.

22Jan 26

Tatva Chintan Pharma Chem Projects Electrolyte Salts Revenue to Reach 7-8% by 2026

Tatva Chintan Pharma Chem has provided guidance projecting electrolyte salts to contribute 7% to 8% of total revenue by calendar year 2026, representing a significant increase from the current 1% contribution. This projection indicates substantial growth potential in the company's electrolyte materials business segment and demonstrates management's strategic focus on diversifying revenue streams through specialized chemical solutions.

21Jan 26

Tatva Chintan Pharma Chem Reports Strong Q3 FY26 Results with Revenue Growth of 52.9%

Tatva Chintan Pharma Chem Limited reported outstanding Q3 FY26 results with consolidated revenue growing 52.9% YoY to ₹1,313.34 million and net profit surging to ₹151.65 million from ₹1.38 million in Q3 FY25. Nine-month revenue reached ₹3,717.14 million, up 35.2% YoY, with net profit increasing 577.7% to ₹317.33 million. The specialty chemicals company demonstrated improved operational efficiency and strong business momentum across its manufacturing operations.

12Jan 26

Tatva Chintan Pharma Chem Limited Schedules Q3FY26 Earnings Call for January 21, 2026

Tatva Chintan Pharma Chem Limited has scheduled its Q3FY26 earnings call for January 21, 2026, at 5:00 PM IST to discuss financial results for the quarter and nine months ended December 31, 2025. The call will be hosted by ICICI Securities and represented by Managing Director Mr. Chintan Shah and CFO Mr. Ajesh Pillai. The company has notified stock exchanges under SEBI regulations and made the information available on its website.

03Nov 25

Tatva Chintan Pharma Chem Reports Impressive Q2 Turnaround with 99.2 Million Rupees Net Profit

Tatva Chintan Pharma Chem Ltd. has achieved a significant financial turnaround in Q2. The company reported a net profit of ₹99.20 crore, compared to a loss of ₹6.64 crore in the same quarter last year. Revenue increased by 48.50% to ₹124.00 crore. EBITDA rose by 296.43% to ₹22.20 crore, with the EBITDA margin expanding from 6.71% to 17.90%. These results indicate substantial improvements in profitability, revenue growth, and operational efficiency.

31Oct 25

Tatva Chintan Pharma Chem Reports Robust Q2 Turnaround with 99.2 Million Rupees Net Profit

Tatva Chintan Pharma posted a net profit of 99.2 million rupees in Q2, recovering from a 6.64 million rupees loss last year. Revenue grew 48.5% to 1.24 billion rupees. EBITDA increased to 222 million rupees with margin expanding to 17.99%. Half-year performance showed total income of 2,425.43 million rupees and net profit of 165.68 million rupees. The company appointed Ajesh Kumar Mohanan Pillai as CFO and KMP.

09Oct 25

Ratan Tata's Rs 1 Lakh Car Vision: Strategic Choices and Political Challenges in Singur

Former Tata associate Niira Radia revealed details about Ratan Tata's vision for the Rs 1 lakh car project, which became the Tata Nano. The project initially shocked Tata's team. Singur, West Bengal, was chosen as the manufacturing site to stimulate industrial growth and for political reasons. However, the project faced land acquisition issues and political opposition, leading to its relocation to Sanand, Gujarat. Radia noted that Tata believed the Singur project could have transformed the region, similar to Sanand's current development.

08Oct 25

Tata Group Refutes Claims of Internal Power Struggle

Sources close to the Tata Group have strongly refuted recent reports suggesting an internal power struggle within Tata Trusts. The claims, which involved Mehli Mistry, first cousin of Cyrus Mistry and a close associate of Ratan Tata, have been dismissed as a 'false narrative'. The sources categorically rejected allegations of Mehli Mistry attempting to gain control within the organization.

06Oct 25

Government to Mediate Tata Group's Internal Board Dispute

The Tata Group is facing a leadership divide between factions led by Noel Tata and Mehli Mistry, leading to disagreements over strategic decisions at Tata Sons. The conflict escalated after a contentious Tata Trusts meeting resulted in Vijay Singh's departure from the Tata Sons board. The Indian government plans to intervene with high-level discussions involving senior central ministers, addressing concerns about potential impacts on the broader corporate sector. Key discussion points include the internal board dispute, Tata Sons' mandatory listing under RBI guidelines, and the company's application to cancel its core investment company registration. Tata Sons has achieved a net zero debt position despite these challenges. Tata Trusts owns 66% of Tata Sons, and the company is awaiting RBI's decision on its request to cancel its core investment company registration to avoid mandatory listing by September 2025.

01Oct 25

Tata Group to Manufacture Airbus H125 Helicopters in Karnataka

The Tata Group has announced plans to manufacture Airbus H125 helicopters in Karnataka, India. The facility is expected to start deliveries by 2027, marking a significant boost to India's aerospace manufacturing capabilities and the 'Make in India' initiative. This strategic partnership between Tata and Airbus combines Indian manufacturing with European aerospace technology. The Airbus H125 is a versatile single-engine light helicopter used in various sectors including law enforcement and emergency medical services.

30Sept 25

Tata Group Stocks Face Headwinds, One Stock Bucks the Trend

Several Tata Group stocks are experiencing significant declines. TCS hit a 52-week low, while Titan saw a sharp 7% drop this month. Tata Elxsi and Tata Technologies showed minimal movement. However, an unidentified Tata Group stock achieved its best monthly performance in over 16 years, standing out amidst the general downturn.

25Jul 25

Tatva Chintan Pharma Chem Reports Strong Q1 Results with 27.7% Profit Growth

Tatva Chintan Pharma Chem Ltd. reported robust Q1 financial results. Revenue from operations increased by 10.8% to ₹1,168.64 crore, while profit after tax surged by 27.7% to ₹66.51 crore. EBITDA expanded by 37.4% to ₹173.30 crore, with operating margins improving to 14.8%. The company saw growth across product categories, particularly in Structure Directing Agents and Pharma & Agrochemical Intermediates segments. The strong performance is attributed to an improved product mix, operational efficiency, and market expansion. With a strong order book and ongoing capacity expansion, Tatva Chintan is positioned for continued growth.

24Jul 25

Tatva Chintan Reports Strong Q1 Performance with 11% Revenue Growth

Tatva Chintan Pharma announced robust Q1 financial results, with consolidated revenue increasing 11% to ₹1,168.64 crore. EBITDA rose 37% year-on-year to ₹173.30 crore, with the margin expanding to 14.8%. Net profit grew 28% to ₹66.50 crore, and EPS increased to ₹2.84. The company's diverse product portfolio contributed to growth, with Pharma & Agrochemical Intermediates (PASC) being the largest segment at 37% revenue contribution. Management changes were announced, including re-appointments of key directors and the resignation of the CFO.

24Jul 25

Tatva Chintan Reports Q1 Results, Approves Director Reappointments and CFO Resignation

Tatva Chintan Pharma Chem Limited reported strong Q1 results with a 10.8% increase in revenue to Rs 1,168.64 million and a 27.7% rise in net profit to Rs 66.51 million. EBITDA grew by 37.4% to Rs 173.30 million, with margin improvement to 14.8%. The Board approved reappointments of key executives and independent directors. CFO Ashok Bothra resigned effective August 30, 2025. The company's product segments showed diverse revenue contributions, with Pharma & Agrochemical Intermediates leading at 37%.

18Jul 25

Tatva Chintan Pharma Chem Surges 14% as Mukul Agrawal Acquires 1.28% Stake

Shares of Tatva Chintan Pharma Chem Limited rose 13.6% to Rs 1,062.70 after prominent investor Mukul Agrawal acquired a 1.28% stake (3 lakh shares) in the company. The stock has rallied 21.4% year-to-date, recovering from a previous 65% decline from its peak. Domestic mutual funds slightly reduced their stake to 5.07%, while Goldman Sachs maintained a 2.59% stake. The company has scheduled a Board meeting and earnings call for July 24 to discuss Q1 FY24 financial results.

18Jul 25

Mukul Mahavir Agrawal Acquires 1.28% Stake in Tatva Chintan Pharma Chem; Company Announces Q1 FY26 Board Meeting

Tatva Chintan Pharma Chem Limited reports a 1.28% stake acquisition by investor Mukul Mahavir Agrawal. The company has scheduled a board meeting on July 24, 2025, to approve Q1 FY26 financial results. An earnings call will follow, featuring key company executives. The trading window for designated persons will be closed from July 1, 2025, until 48 hours after the results announcement.

17Jul 25

Mukul Mahavir Agrawal Acquires 1.28% Stake in Tatva Chintan Pharma Chem; Company Schedules Q1 FY26 Results

Investor Mukul Mahavir Agrawal has acquired a 1.28% stake in Tatva Chintan Pharma Chem Limited during the first quarter. The company's Board of Directors will meet on July 24, 2025, to approve Q1 FY26 financial results, followed by an earnings call featuring key company representatives. The trading window for the company's equity shares will be closed from July 1, 2025, until 48 hours after the Q1 FY26 results are made public.

18Jun 25

CRISIL Downgrades Tatva Chintan Pharma Chem's Ratings Amid Business Challenges

CRISIL has downgraded Tatva Chintan Pharma Chem Ltd's ratings on bank facilities worth ₹245.00 crore. Long-term rating revised from A- (negative) to BBB+ (stable), and short-term rating from A2+ to A2. The downgrade is due to expected revenue decline to ₹385.00 crore and operating profit margin compression to 9.49% from 18.43%.

05May 25

Tatva Chintan Pharma Chem Secures ₹29.95 Crore Export Order for Specialty Chemicals

Tatva Chintan Pharma Chem Limited has received a significant export order worth ₹29.95 crore (USD 3.56 million) for supplying specialty chemicals in the Pharma & Agro Intermediates & Specialty Chemicals (PASC) category. The order, placed by an international client, is set for delivery in November/December 2025. This development is expected to boost the company's revenue for Q3 FY26 and strengthen its position in the global specialty chemicals market.

05May 25

Tatva Chintan Pharma Chem Reports Q4 Profit Surge, Recommends Dividend

Tatva Chintan Pharma Chem Ltd. (TCPCL) reported a significant improvement in Q4 FY2024-25 financials. Net profit rose to ₹10.30 crore from ₹1.38 crore in Q3, though down from ₹96.00 crore year-over-year. Revenue increased by 5.64% YoY to ₹108.60 crore. The company showed substantial QoQ improvements in revenue (26.43% increase) and EBITDA (36.62% increase). Despite YoY challenges, TCPCL demonstrated resilience with improved quarterly performance. A final dividend of ₹1.00 per equity share was recommended.

02May 25

Tatva Chintan Pharma Chem Reports Mixed Q4 Results, Recommends Dividend

Tatva Chintan Pharma Chem Limited reported mixed financial results for Q4 and FY 2024-25. Q4 revenue increased 9.80% YoY to ₹1,078.64 crore, but net profit fell to ₹10.30 crore from ₹96.14 crore. FY25 saw a marginal decrease in annual revenue to ₹3,827.14 crore, with net profit declining 68.30% to ₹96.14 crore. Despite challenges, a final dividend of ₹1 per share was recommended. The company faces profitability pressures but shows resilience in revenue growth amid sector headwinds.